| Aim:To explore the efficacy and toxicity of the FOLFOX4reimen as neoadjuvant chemotherpy in the treatment of advanced gastric cancer.Method:Sixty patients with advanced gastric cancer were treated with FOLFOX4regimen as neoadjuvant chemotherapy. The regimen consisted of oxaliplatin200mg/m2, ivdrip, d1; calcium folinate200mg/m2,ivdrip, d1-d5;5-FU200mg/m2or FT-2071000mg/m2, ivdrip, d1-d5. Altogether2cycles,2times interval3～4weeks chemotherapy. Observe the changes of clinical symptoms, side effects of chemothera-py, alleviate tumor markers CA19-9and imaging changes.Result:The treatment response rates (CR+PR) were70%(42/70); The operation excision rate of patients was69.9%;The most common toxicities were leuko, pinia, nausea, vomiting and periphery neurotoxicity; All of the60patients were well tolerated the FOLFOX4scheme neoadjuvant chemotherapy, none of them exit the experiment cause of the side effects of chemotherapy. Though some patients serum CA19-9values decresaed after two times neoadjuvant chemotherpy, but statistical analyse showed the rusult has no meaning (P>0.05).Conclusion:1.The FOLFOX4regimen as neoadjuvant chemotherapy for the pa-tients with advanced gastric cancer is an effective and well-tolerated treatment.2.Though some patients serum CA19-9values decresaed during the neoadjuvant chemotherpy of advanced gastric carcinoma, this can not reflects the real therapeutic effect. So we consider that there is no necessary to survey the changes of CA19-9during the neoadjuvant chemotherpy of advanced gastric carcinoma. |
PDF Full Text Request